We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: SGLT2 inhibitors
MedXY News
EnglishTag

SGLT2 inhibitors

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study
Dermatologyatopic dermatitisdiabetes

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY|Nov 1, 2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial
Nephrologybone healthDapagliflozin

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY|Oct 30, 2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors’ bone safety in this population.

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection
CardiologyCardiac Remodelingchronic kidney disease

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY|Oct 30, 2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction
Clinical UpdatesAlzheimer's diseaseGLP-1 receptor agonists

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY|Oct 9, 2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits

Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects
Clinical UpdatesSGLT2 inhibitorstype 2 diabetes

Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects

By MedXY|Oct 8, 2025

A randomized placebo-controlled trial demonstrates that henagliflozin improves telomere length and multiple aging biomarkers in patients with type 2 diabetes, suggesting potential anti-aging benefits beyond glucose control.

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis
CardiologyDapagliflozinheart failure

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

By MedXY|Oct 6, 2025

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF i

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study
Clinical Updateschronic kidney diseasekidney function

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study

By MedXY|Oct 4, 2025

A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy
Clinical UpdatesBeta-cell functionDapagliflozin

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY|Oct 4, 2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes
Diabetes & EndocrinologyGlycemic Controlrenal function

Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes

By MedXY|Oct 4, 2025

SGLT2 inhibitors adjunct to insulin improve glycemic control, reduce hyperfiltration, and are generally safe in youth with type 1 diabetes under careful ketone monitoring and DKA risk mitigation.

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
Cardiologycardiovascular outcomesOral Semaglutide

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY|Oct 3, 2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes
Clinical Updatesdiabetesmortality risk

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes

By MedXY|Oct 3, 2025

Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial
Cardiologyempagliflozinheart failure

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

By MedXY|Oct 3, 2025

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors
Cardiologyerythrocytosisheart failure

Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors

By MedXY|Oct 2, 2025

This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over o

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction
Cardiologyclinical trialheart failure

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction

By MedXY|Oct 2, 2025

The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities